Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study

Abstract The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients...

Full description

Bibliographic Details
Main Authors: Ann Janssens, Zwi N. Berneman, Fritz Offner, Sylvia Snauwaert, Philippe Mineur, Gaetan Vanstraelen, Stef Meers, Isabelle Spoormans, Dominique Bron, Isabelle Vande Broek, Charlotte Van Bogaert, Birgit De Beleyr, Ann Smet, Lasse Nielsen, Robert Wapenaar, Marc André
Format: Article
Language:English
Published: SAABRON PRESS 2022-10-01
Series:Clinical Hematology International
Subjects:
Ibrutinib
Chronic lymphocytic leukemia
Belgium
Real-world evidence
Effectiveness
Safety
Online Access:https://doi.org/10.1007/s44228-022-00020-8

Similar Items

Similar Items